Article
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2022
Minchom Anna, Viteri Santiago, Bazhenova Lyudmila, Gadgeel Shirish M, Ou Sai-Hong Ignatius, Trigo José, Bauml Joshua M, Backenroth Daniel, Bhattacharya Archan, Li Tracy, Mahadevia Parthiv, Girard Nicolas
Abstract excerpt
BACKGROUND: In the single-arm CHRYSALIS study, amivantamab showed durable responses and manageable safety in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who progressed on prior platinum-based chemotherapy. External controls can provide context for interpreting amivantamab efficacy. METHODS: External controls were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.